| 0.7741 0.063 (8.87%) | 11-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.31 | 1-year : | 1.63 |
| Resists | First : | 1.12 | Second : | 1.39 |
| Pivot price | 0.8  |
|||
| Supports | First : | 0.68 | Second : | 0.56 |
| MAs | MA(5) : | 0.72 |
MA(20) : | 0.91 |
| MA(100) : | 1.22 |
MA(250) : | 1.06 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.6 |
D(3) : | 5.9 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 2.92 | Low : | 0.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BRNS ] has closed above bottom band by 43.5%. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.82 | 0.82 - 0.83 |
| Low: | 0.71 - 0.71 | 0.71 - 0.71 |
| Close: | 0.77 - 0.77 | 0.77 - 0.78 |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Mon, 17 Nov 2025
BRNS: HC Wainwright & Co. Raises Price Target for Barinthus Biot - GuruFocus
Fri, 07 Nov 2025
Barinthus Biotherapeutics plc. SEC 10-Q Report - TradingView
Fri, 07 Nov 2025
Barinthus Biotherapeutics Reports Q3 2025 Earnings - TipRanks
Fri, 07 Nov 2025
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments - GlobeNewswire
Wed, 08 Oct 2025
Fox Williams Advises Clywedog Therapeutics in Proposed Merger with Barinthus Biotherapeutics - Fox Williams
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 44 (%) |
| Shares Short | 41 (K) |
| Shares Short P.Month | 123 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -62.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|